Apollomics Inc. - Class A

The momentum for this stock is not very good. Apollomics Inc. - Class A is not very popular among insiders. Tradey thinks it is not wise to invest in Apollomics Inc. - Class A.

News

Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Globe Newswire FOSTER CITY, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) ( Apollomics or the Company ), a late-stage clinical biopharmaceutical company developing multiple oncology...\n more…

Apollomics, Inc. (NASDAQ:APLM) Sees Large Increase in Short Interest

Zolmax Apollomics, Inc. (NASDAQ:APLM - Get Free Report) was the target of a significant increase in short interest in the month of August. As of August 15th, there was short interest totalling 2,790,000...\n more…

Financial Survey: Apollomics (NASDAQ:APLM) and Dianthus Therapeutics (NASDAQ:DNTH)

Zolmax Apollomics (NASDAQ:APLM - Get Free Report) and Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two...\n more…

Apollomics, Inc. (NASDAQ:APLM) Short Interest Up 607.0% in August

Ticker Report Apollomics, Inc. (NASDAQ:APLM - Get Free Report) was the recipient of a large increase in short interest in August. As of August 15th, there was short interest totalling 2,790,000 shares, an increase...\n more…

Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress

Globe Newswire Continued clinical progress for the vebreltinib registration-enabling program, including new data in non-CNS MET fusion tumors and non-small cell lung cancer (NSCLC) with MET amplification $25.9...\n more…

Why Is Penny Stock Apollomics Trading Higher On Tuesday?

Benzinga Apollomics shares soared after revealing promising Phase 2 SPARTA trial data for vebreltinib in non-CNS MET fusion solid tumors, showing a 43% ORR with notable responses in metastatic NSCLC, pancreatic, and bile duct cancers.\n more…